Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 20:04:36时区推断·⟳ 抓取 20:07:48·⚡ 决策 07-28 20:09:58 +2m10s·91.1 天前
Nuwellis在威斯康星儿科医院安装Aquadex系统但未披露金额
这是公司新闻稿式的单院安装进展，未披露采购金额、装机数量、收入确认节奏或对利润的影响。
📄 原文Investing.com↗ 原文
Nuwellis installs Aquadex systems at Wisconsin pediatric hospital
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE) an…
不做 Nuwellis（NUWE.US）
单院安装新闻未披露金额、数量或收入贡献，且FDA儿科扩标仍未递交申请，事件级别太小，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 medium ↗
关键理由
- 这是公司新闻稿式的单院安装进展，未披露采购金额、装机数量、收入确认节奏或对利润的影响。
- Aquadex儿科适应症扩展仍停留在FDA预提交会议后、预计2026年底递交510(k)阶段，尚非获批或商业化放量节点。
主要风险
- 微型医疗器械公司单点医院安装容易被当作营销性采用新闻，缺少可回测的短周期业绩增量。
- 若后续披露大额采购合同或FDA正式扩标获批，应作为新催化重新研判。
原文全文
展开原文 · 1,966 字
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation
MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE) announced today the installation of its Aquadex SmartFlow systems at a pediatric healthcare institution in Wisconsin, marking the company’s first entry into the state’s market.
The medical technology company installed the systems at an academic medical center, according to a press release statement. The Aquadex SmartFlow System provides ultrafiltration therapy for adult and pediatric patients weighing 20 kilograms and above who suffer from fluid overload unresponsive to diuretics.
"Establishing our first pediatric program in Wisconsin reflects the continued momentum of our pediatric growth and increasing clinical adoption of our Aquadex therapy," said CEO Mike McCormick.
The installations will support the development of clinical pathways and integrate Aquadex therapy into the hospital’s pediatric care program. Nuwellis stated that pediatric programs represent a strategic growth opportunity for the company.
The company completed a pre-submission meeting with the U.S. Food and Drug Administration regarding a proposed expansion of the Aquadex label to support pediatric patients weighing 5 kilograms and above. Nuwellis anticipates submitting a 510(k) application to the FDA for the expanded label by the end of 2026.
The Aquadex SmartFlow System is currently indicated for continuous ultrafiltration therapy for temporary or extended use in patients whose fluid overload is unresponsive to medical management. All treatments must be administered by a healthcare provider within an outpatient or inpatient clinical setting under physician prescription.
Nuwellis develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE) announced today the installation of its Aquadex SmartFlow systems at a pediatric healthcare institution in Wisconsin, marking the company’s first entry into the state’s market.
The medical technology company installed the systems at an academic medical center, according to a press release statement. The Aquadex SmartFlow System provides ultrafiltration therapy for adult and pediatric patients weighing 20 kilograms and above who suffer from fluid overload unresponsive to diuretics.
"Establishing our first pediatric program in Wisconsin reflects the continued momentum of our pediatric growth and increasing clinical adoption of our Aquadex therapy," said CEO Mike McCormick.
The installations will support the development of clinical pathways and integrate Aquadex therapy into the hospital’s pediatric care program. Nuwellis stated that pediatric programs represent a strategic growth opportunity for the company.
The company completed a pre-submission meeting with the U.S. Food and Drug Administration regarding a proposed expansion of the Aquadex label to support pediatric patients weighing 5 kilograms and above. Nuwellis anticipates submitting a 510(k) application to the FDA for the expanded label by the end of 2026.
The Aquadex SmartFlow System is currently indicated for continuous ultrafiltration therapy for temporary or extended use in patients whose fluid overload is unresponsive to medical management. All treatments must be administered by a healthcare provider within an outpatient or inpatient clinical setting under physician prescription.
Nuwellis develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。